|
|
|
@ -53,7 +53,7 @@
|
|
|
|
|
- ## Objetivos y logros de los proyectos STOP previos (en background)
|
|
|
|
|
- Qualification at EMA for art. 58
|
|
|
|
|
- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
|
|
|
|
|
- Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa
|
|
|
|
|
- Demonstrated efficacy against T. trichiura in a pivotal trial in Sub-Saharan Africa
|
|
|
|
|
- No stopping rules were reached
|
|
|
|
|
- Safety was adequate
|
|
|
|
|
- Palatability results confirm adecuacy of size, taste and smell
|
|
|
|
@ -85,4 +85,4 @@
|
|
|
|
|
- ## HOME
|
|
|
|
|
- ### Background
|
|
|
|
|
- Especificar que la novel formulation es una fixed-dose coformulation de [[Ivermectina]] y [[Albendazol]].
|
|
|
|
|
- Especificar que esta fixed-dose coformulation de ivm/alb es la lower
|
|
|
|
|
- Especificar que esta fixed-dose coformulation de ivm/alb has the lowest level of investment risk of all candidates for Combi
|